The high expression of the microRNA 17-92 cluster and its paralogs, and the downregulation of the target gene PTEN, is associated with primary cutaneous B-cell lymphoma progression

Journal of Investigative Dermatology

Volumn 135, Issue 6, 2015, Pages 1659-1667

  Battistella, Maxime ^a,b,c   Romero, Martha ^a,d   Castro Vega, Luis Jaime ^b,e   Gapihan, Guillaume ^a,b   Bouhidel, Fatiha ^a,b,c   Bagot, Martine ^a,b,c   Feugeas, Jean Paul ^a   Janin, Anne ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

^e PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAPRIN2 PROTEIN; CD20 ANTIGEN; CHLORAMBUCIL; CYP4V2 PROTEIN; HLA B ANTIGEN; MESSENGER RNA; MICRORNA; MICRORNA 106A; MICRORNA 106A-363; MICRORNA 106B; MICRORNA 106B-25; MICRORNA 17; MICRORNA 17-92; MICRORNA 18A; MICRORNA 18B; MICRORNA 19A; MICRORNA 19B; MICRORNA 20A; MICRORNA 20B; MICRORNA 25; MICRORNA 363; MICRORNA 92A; MICRORNA 93; MLLT6 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOLIPASE A2 GROUP VI; PROTEIN; RITUXIMAB; STEROID RECEPTOR COACTIVATOR 3; TTC7A PROTEIN; UNCLASSIFIED DRUG; MIRN17-92 MICRORNA, HUMAN; PTEN PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER MODEL; CONTROLLED STUDY; CUTANEOUS DIFFUSE LARGE B CELL LYMPHOMAS; CUTANEOUS FOLLICLE CENTER LYMPHOMA; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LARGE CELL LYMPHOMA; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RADIATION RESPONSE; SKIN BIOPSY; SKIN LYMPHOMA; TREATMENT RESPONSE; UNINDEXED SEQUENCE; UPREGULATION; APOPTOSIS; BIOLOGY; BIOPSY; DISEASE COURSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MULTIGENE FAMILY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SKIN; SKIN TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD20; APOPTOSIS; BIOPSY; COMPUTATIONAL BIOLOGY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MICRORNAS; MIDDLE AGED; MULTIGENE FAMILY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PTEN PHOSPHOHYDROLASE; RNA, MESSENGER; SKIN; SKIN NEOPLASMS;

EID: 84938063872     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2015.27     Document Type: Article

References (53)

1. Akbari Moqadam F, Pieters R, den Boer ML (2013) The hunting of targets: challenge in miRNA research. Leukemia 27:16-23
2. Alencar AJ, Malumbres R, Kozloski GA et al. (2011) MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res 17:4125-35
3. Auer RL (2011) The coming of age of microRNA for B cell lymphomas. Histopathology 58:39-48
4. Baek D, Villen J, Shin C et al. (2008) The impact of microRNAs on protein output. Nature 455:64-71
5. Burg G, Kempf W, Cozzio A et al. (2005) WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol 32:647-74
6. Castellano L, Giamas G, Jacob J et al. (2009) The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci USA 106:15732-7
7. Fabbri M, Croce CM (2011) Role of microRNAs in lymphoid biology and disease. Curr Opin Hematol 18:266-72
8. Fassina A, Marino F, Siri M et al. (2012) The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies. Lab Invest 92: 1574-82
9. Friedman RC, Farh KK, Burge CB et al. (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19:92-105
10. Gottwein E, Corcoran DL, Mukherjee N et al. (2011) Viral microRNA targetome of KSHV-infected primary effusion lymphoma cell lines. Cell Host Microbe 10:515-26
11. Grange F, Bekkenk MW, Wechsler J et al. (2001) Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol 19:3602-10
12. Grange F, Beylot-Barry M, Courville P et al. (2007) Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol 143:1144-50
13. Grange F, Joly P, Barbe C et al. (2014) Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. JAMA Dermatol 150:535-41
14. He L, Thomson JM, Hemann MT et al. (2005) A microRNA polycistron as a potential human oncogene. Nature 435:828-33
15. Hoefnagel JJ, Dijkman R, Basso K et al. (2005) Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 105:3671-8
16. Inomata M, Tagawa H, Guo YM et al. (2009) MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood 113:396-402
17. Jiang P, Rao EY, Meng N et al. (2010) MicroRNA-17-92 significantly enhances radioresistance in human mantle cell lymphoma cells. Radiat Oncol 5:100
18. Jin HY, Oda H, Lai M et al. (2013) MicroRNA-17B92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. EMBO J 32:2377-91
19. Kim YH, Willemze R, Pimpinelli N et al. (2007) TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110:479-84
20. Kodama K, Massone C, Chott A et al. (2005) Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood 106:2491-7
21. Koens L, Qin Y, Leung WY et al. (2013) MicroRNA profiling of primary cutaneous large B-cell lymphomas. PLoS One 8:e82471
22. Lenz G, Wright GW, Emre NC et al. (2008) Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 105:13520-5
23. Liu YY, Yao SN, Zhao Y et al. (2010) PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma. Leuk Lymphoma 51:1692-8
24. Mendell JT (2008) miRiad roles for the miR-17-92 cluster in development and disease. Cell 133:217-22
25. Mogilyansky E, Rigoutsos I (2013) The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ 20:1603-14
26. Monsalvez V, Montes-Moreno S, Artiga MJ et al. (2013) MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma. Mod Pathol 26:171-81
27. Navarro A, Bea S, Fernandez V et al. (2009) MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermuta-tions in Mantle cell lymphomas. Cancer Res 69:7071-8
28. Pende D, Rivera P, Marcenaro S et al. (2002) Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 62:6178-86
29. Pennartz S, Belvindrah R, Tomiuk S et al. (2004) Purification of neuronal precursors from the adult mouse brain: comprehensive gene expression analysis provides new insights into the control of cell migration, differentiation, and homeostasis. Mol Cell Neurosci 25:692-706
30. Pfeifer M, Grau M, Lenze D et al. (2013) PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 110:12420-5
31. Pham-Ledard A, Beylot-Barry M, Barbe C et al. (2014) High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type. JAMA Dermatol 150:1173-9
32. Rao E, Jiang C, Ji M et al. (2012) The miRNA-17 approximately 92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia 26:1064-72
33. Riley KJ, Rabinowitz GS, Yario TA et al. (2012) EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency. EMBO J 31:2207-21
34. Romanski A, Bug G, Becker S et al. (2005) Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol 33:344-52
35. Senff NJ, Hoefnagel JJ, Jansen PM et al. (2007) Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol 25:1581-7
36. Senff NJ, Noordijk EM, Kim YH et al. (2008) European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112:1600-9
37. Senff NJ, Willemze R (2007) The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group. Br J Dermatol 157:1205-11
38. Smith BD, Smith GL, Cooper DL et al. (2005) The cutaneous B-cell lymphoma prognostic index: a novel prognostic index derived from a population-based registry. J Clin Oncol 23:3390-5
39. Song MS, Salmena L, Pandolfi PP (2012) The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13:283-96
40. Stern-Ginossar N, Gur C, Biton M et al. (2008) Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol 9:1065-73
41. Swerdlow SH, Campo E, Harris NL et al. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn.vol. 2. IARC Press: Lyon, France, 439
42. Thapa DR, Li X, Jamieson BD et al. (2011) Overexpression of microRNAs from the miR-17-92 paralog clusters in AIDS-related non-Hodgkin's lympho-mas. PLoS One 6:e20781
43. Trompeter HI, Abbad H, Iwaniuk KM et al. (2011) MicroRNAs MiR-17, MiR-20a, and MiR-106b act in concert to modulate E2F activity on cell cycle arrest during neuronal lineage differentiation of USSC. PLoS One 6:e16138
44. Tsukerman P, Stern-Ginossar N, Gur C et al. (2012) MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells. Cancer Res 72:5463-72
45. Ventura A, Young AG, Winslow MM et al. (2008) Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132:875-86
46. Vogel C, Marcotte EM (2012) Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet 13: 227-32
47. Volinia S, Calin GA, Liu CG et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103:2257-61
48. Volinia S, Galasso M, Costinean S et al. (2010) Reprogramming of miRNA networks in cancer and leukemia. Genome Res 20:589-99
49. Westin JR (2014) Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma. Clin Lymphoma Myeloma Leuk 14:335-42
50. Willemze R, Jaffe ES, Burg G et al. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-85
51. Xiao C, Srinivasan L, Calado DP et al. (2008) Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9:405-14
52. Zhang JX, Song W, Chen ZH et al. (2013) Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol 14:1295-306
53. Zhu H, Han C, Lu D et al. (2014) miR-17-92 cluster promotes cholangiocarci-noma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator. Am J Pathol 184:2828-39